Photo Credit: yogenyogeny

The following is a summary of “Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes,” published in the December 2024 issue of Ophthalmology by Panse et al. 

Researchers conducted a retrospective study to evaluate clinically relevant outcomes following suprachoroidal triamcinolone acetonide (TA) injection in eyes with noninfectious uveitis.  

They examined 61 eyes (51 patients) that received suprachoroidal TA injection between January 1, 2022, and July 1, 2024, from a single institution. The primary outcome measures were changes in central subfield thickness (CST) and best-corrected visual acuity (BCVA) at 6, 12, and 24 weeks in eyes with macular edema. Additionally, improvement in fluorescein angiography (FA) score at 6 weeks was assessed in eyes that underwent FA.  

The results showed 52 eyes received suprachoroidal TA injection for uveitic macular edema. The mean CST decreased from 437.61 microns at injection to 348.17 microns at 6 weeks (mean difference 89.44 microns, P <0.0001, n=47). Additional treatment for macular edema was required in 17% (8/48 eyes), 48% (14/29 eyes), and 41% (9/22 eyes) of eyes at follow-up visits at 6, 12, and 24 weeks, respectively, of the 17 eyes that returned for all follow-up visits (6, 12, and 24 weeks), 41.2% (7/17 eyes) did not need further treatment during the 24 weeks, FA was performed on 10 eyes at baseline and 6 weeks later, with the mean FA score improving from 11.74 to 9.14 (mean difference 2.60, P =0.047). No serious adverse events were reported.  

Investigators concluded the suprachoroidal TA significantly improved outcome measures, including CST in eyes with macular edema and leakage on FA, with a favorable side effect profile in real-world clinical practice. 

Source: ajo.com/article/S0002-9394(24)00554-3/abstract